MAM
BBC World appoints Vyas Giannetti & MediaCom as its creative and media agencies
MUMBAI: BBC World has assigned creative and media duties in India to Vyas Giannetti Creative and MediaCom India respectively. The agencies will be responsible for providing a creative and effective communication strategy to build on the positioning and reputation of BBC.
Announcing the appointment of the agencies, BBC World head of marketing Seema Kotecha says, “This review gave us an opportunity to witness exceptional ideas presented by some of India’s best agencies. There is a lot of creative talent here and it was a difficult decision. Vyas Giannetti and MediaCom India demonstrated an excellent understanding of the brand, evident in their innovative and strategic recommendations. We believe they will provide the right level of support for the brand in this highly competitive market.”
In August, BBC World invited a number of agencies from Delhi and Mumbai to pitch for the channel’s creative and media responsibilities. The pitch process saw top agencies presenting their ideas and strategies to support the channel’s marketing objectives.
Vyas Giannetti Creative chairperson and chief creative officer Preeti Vyas Giannetti says, “BBC World is trusted and respected globally for its journalistic excellence and extensive analysis of international news. We are very happy to be associated with the BBC World brand, and provide creative support to strengthen the channel’s positioning in India.”
MediaCom president – South Asia Jasmin Sohrabji adds, “We are honoured to have been selected as the media agency for BBC World in India. We look forward to this challenging assignment to effectively and innovatively reach out to the channel’s core audience in this market.”
In April this year, BBC World launched its biggest ever brand campaign in India, Putting News First. Working closely with the appointed agencies, the channel will build and develop the next phase of the campaign, reflecting its core strengths of cutting-edge journalism and world-class news reportage.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
